Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Results demonstrate, ToleroMune therapy can reduce both nasal and ocular allergy symptom levels
Subscribe to our email newsletter
Circassia has reported positive results from a recently completed phase II clinical study of ToleroMune cat allergy therapy, which successfully identified the optimal dosing regimens to progress into late-stage development.
The clinical trial showed that Circassia’s ToleroMune treatment was extremely well tolerated and greatly reduced sufferers’ symptoms.
The double-blind study was conducted in Canada, where 121 subjects with confirmed cat allergies were randomised to receive placebo or one of four different treatment regimes with standardised doses of ToleroMune.
The volunteers were exposed to cat allergens (aerosolised dander) in an environmental exposure chamber for 3 hours each day on four consecutive days, both before and after treatment. At set time points the subjects scored their ocular and nasal symptoms to allow investigators to measure the effect of the ToleroMune treatment.
The study’s results demonstrate that ToleroMune therapy can reduce both nasal and ocular allergy symptom levels, and that the treatment effect grows as the duration of exposure increases and symptoms are at their greatest.
The optimal regimen decreased total symptom scores by 67% compared with placebo. Throughout the study ToleroMune treatment was extremely well tolerated, with a safety profile similar to placebo.
Steve Harris, CEO of Circassia, said: “These positive phase II results are extremely important for Circassia as they identify the optimal treatment regime to move into the final stages of development for our cat allergy therapy, and will prove invaluable as we progress our broader portfolio of ToleroMune products.
“We are particularly pleased that the ToleroMune treatment achieved such a marked improvement in ocular symptoms, which can be a particular problem in cat allergy. As well as benefiting patients, this effect scientifically validates the ToleroMune approach and its novel focus on generating regulatory T-cells to shut down this type of IgE-mediated allergic response.”